U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07144293) titled 'Improving Physical Ability and Cellular Senescence Elimination in HIV' on Aug. 20.
Brief Summary: This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression.
Participants will be randomly assigned to one of two groups: one group wi...